Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Long Huynh-duc (NPI 1447572169)

Field	Value
Entity Type	Individual
Organization	Long Huynh-duc
Address	50 International Dr Ste 325
City	Greenville
State	SC
ZIP	29615
Taxonomy	Rheumatology Physician
NPI Enumerated	February 22, 2010

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

This provider is heavily infusion-focused: the practice’s top revenue drivers are injectable biologics such as J0717 (certolizumab), J0129 (abatacept), and J1602 (golimumab), consistent with a rheumatology infusion/administration service line rather than a visit-driven outpatient clinic. The provider’s lifetime Medicare revenue of $3.2M and the code mix indicate most income is generated from specialty drug administration rather than traditional office evaluation and management encounters.

Revenue is highly concentrated in a small set of biologic codes: the precomputed top 3 Medicare codes by revenue account for 49.0% of this provider’s total Medicare revenue, led by J0717 ($580.8K, 17.8%), J0129 ($559.4K, 17.2%), and J1602 ($454.5K, 14.0%). This concentration shows the practice’s financial exposure and dependence on a few high-cost injectable therapies.

Payer mix is effectively single-payer Medicare: total Medicare revenue is $3.2M while there is no Medicaid billing on file, indicating the provider operates without a measurable Medicaid revenue stream and is heavily reliant on Medicare volume and reimbursement policies. Analysts should treat this provider as Medicare-dependent when modeling reimbursement risk or negotiating payer arrangements.

Operationally, the practice appears equipped for extended infusion services and complex biologic administration: in addition to the top biologics, the provider bills J9312 (rituximab, $434.7K), J1745 (infliximab, $297.5K), and infusion-related chemotherapy administration codes such as 96413 ($87.5K) and 96401 ($45.6K). In contrast, office E/M codes produce a much smaller share of revenue (99214 at $79K, 2.4%; 99213 at $12.6K, 0.4%), reinforcing that drug/infusion administration drives the business model.

Competitive standing is mixed by code: the provider reports notably above-typical national volume for some infusion biologics (J1602 ranks #58 of 1041, 95th percentile; J1745 ranks #62 of 1352, 95th percentile), while other high-revenue codes are at more typical but still elevated national positions (J0717 ranks #67 of 848, 92th percentile; J0129 ranks #196 of 1221, 84th percentile). These ranks indicate the provider is a major, above-average national participant for certain IV biologics rather than a singular dominant national leader across all rheumatology drugs.

There are clear statistical outlier signals around infusion/chemotherapy administration: 96413 is labeled an "extreme outlier, far above typical national volume for this code" (ranks #103 of 7514, 99th percentile), and add-on infusion hours 96415 and subcutaneous chemo administration 96401 are at the 98th percentile. These outlier labels suggest the practice operates an infusion capacity and delivers prolonged or frequent infusions at volumes uncommon among peers, which has implications for staffing, accreditation, and supply chain.

The clinical scope includes bone-health biologics and osteoporosis therapies alongside rheumatologic biologics: the provider bills J0897 (denosumab, $163.1K, 5.0%) and J3111 (romosozumab, $114.2K, 3.5%), with J0897 at an elevated national percentile (87th). This indicates supplemental services for skeletal disease and fracture prevention are part of the service mix rather than purely disease-modifying rheumatology drugs.

The provider has an established presence with an NPI enumerated 2010-02-22 (~16 years ago), indicating long tenure in the market and likely an established infusion infrastructure and referral relationships. That longevity, combined with the concentrated biologic revenue mix, suggests a stable, mature practice model focused on high-cost injectable therapies under Medicare.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

31 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	145,200	$1	$580.8K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	16,950	$30	$559.4K
J1602	Injection, golimumab, 1 mg, for intravenous use	45,450	$10	$454.5K
J9312	Injection, rituximab, 10 mg	6,900	$60	$434.7K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	11,900	$30	$297.5K
J3262	Injection, tocilizumab, 1 mg	40,040	$10	$200.2K
J0490	Injection, belimumab, 10 mg	5,200	$40	$192.3K
J0897	Injection, denosumab, 1 mg	9,060	$20	$163.1K
J3111	Injection, romosozumab-aqqg, 1 mg	14,280	$10	$114.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	940	$90	$87.5K

Showing 1–10 of 31

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 31 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Long Huynh-duc — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

31 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	13	40	9,640	$30	$424.2K
J0717	2	20	59,200	$1	$278.4K
J1602	4	40	23,560	$10	$264.5K
J3262	13	20	40,900	$1	$202.7K
J9312	2	20	2,340	$60	$193.7K
J0490	3	10	4,820	$40	$152K
J3111	16	40	12,390	$10	$129.4K
J1745	4	50	3,250	$30	$107K
J0897	38	250	2,400	$20	$91.2K
99214	479	7,860	160	$80	$23.2K

Showing 1–10 of 31

Related Providers

Other providers that share a Tax Identification Number (TIN) with Long Huynh-duc, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Richard Kim	SC	Rheumatology Physician	$3.6M	$0
Suhail Kumar	SC	Rheumatology Physician	$3.4M	$0
Corey Ephrussi	SC	Rheumatology Physician	$1.8M	$1.2K

Nearby Providers

Other providers in the same ZIP code as Long Huynh-duc, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Childrens Medical Center	SC	Specialist	$0	$17.1M
Prisma Health University Medical Group	SC	Developmental - Behavioral Pediatrics Physician	$0	$16M
Agapi Behavioral Consultants	SC	Behavior Analyst	$0	$15M
St Francis Hospital, Inc.	SC	General Acute Care Hospital	$0	$13M
Eastside Pediatric Dentistry PA	SC	Pediatric Dentistry	$0	$10M
Magnolia Medical Group Inc	SC	Physical Therapist	$0	$9.9M
Greenville Health Corporation	SC	Durable Medical Equipment & Medical Supplies	$0	$8.9M
D&s Community Services Sc, LLC	SC	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$8.3M
Bloom Behavioral Therapy LLC	SC	Mental Health Counselor	$0	$7.5M
Prisma Health-upstate	SC	General Acute Care Hospital	$0	$6.4M

Long Huynh-duc — Billing Profile & Reimbursement Data

Sign up for Long Huynh-duc — Billing Profile & Reimbursement Data policy alerts

Long Huynh-duc — Billing Profile & Reimbursement Data

Sign up for Long Huynh-duc — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References